Grace Therapeutics, Inc. Net Fee Amt
Grace Therapeutics, Inc. (GRCE) had Net Fee Amt of $1.45 thousand as of 2026-08-24, per its S-3 filed 2026-08-24.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-24
- 2026-08-24: Net Fee Amt $1.45K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-24 | $1.45K S-3 · filed 2026-08-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |